FAST4WARD: Implications for the clinician

International Journal of Clinical Practice

Volumn 63, Issue 7, 2009, Pages 986-988

  Massarotti, E M ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; ATLIZUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; PLACEBO; PREDNISONE; RITUXIMAB; SORBITOL; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN F(AB) FRAGMENT; MACROGOL DERIVATIVE; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ANKYLOSING SPONDYLITIS; BACTERIAL INFECTION; CLINICAL FEATURE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; CROHN DISEASE; DEMYELINATING DISEASE; DISEASE ACTIVITY; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EXPERIENCE; FOOD AND DRUG ADMINISTRATION; GROUPS BY AGE; HUMAN; INJECTION SITE PAIN; INJECTION SITE REACTION; JUVENILE RHEUMATOID ARTHRITIS; LUPUS LIKE SYNDROME; LYMPHOPROLIFERATIVE DISEASE; MONOTHERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; SHORT SURVEY; SINGLE DRUG DOSE; TUBERCULOSIS; ADOLESCENT; ADULT; AGED; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; MIDDLE AGED; MULTICENTER STUDY (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; POLYETHYLENE GLYCOLS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED;

EID: 67650741864     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2009.02095.x     Document Type: Short Survey

References (17)

1. Weisman MH. Progress towards the cure of rheumatoid arthritis? The BeSt study Arthritis Rheum 2005 52 : 3326 32.
2. Ellerin TH, Rubin RH, Weinblatt ME. Infections and anti tumor necrosis alpha therapy. Arthritis Rheum 2003 48 : 3013 22.
3. Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002 46 : 3151 8.
4. Shin IS, Baer AN, Kwon HJ, Papadopoulos EJ, Siegel JN. Guillain-Barré and Miller Fisher syndromes occurring with tumor necrosis factor alpha antagonist therapy. Arthritis Rheum 2006 54 : 1429 34.
5. Nesbitt A, Fossati G, Bergin M et al. Mechanism of action of certolizumab pegol (CDP870): In vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis 2007 13 : 1323 232.
6. Fleischmann R, Vencovsky J, van Vollenhoven R et al. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann Rheum Dis 2008. Published online 17 Nov 2008; doi :.
7. Ramos-Casals M, Brito-Zeron P, Munoz S et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 2007 86 : 242 51.
8. Elliott MJ, Maini RN, Feldmann M et al. Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet 1994 344 : 1125 7.
9. Saag KG, Teng GG, Patkar NM et al. American College of Rheumatology 2008 Recommendations for the Use of Nonbiologic and Biologic Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis. Arthritis Rheum 2008 59 : 762 84.
10. St Clair EW, van der Heijde DM, Smolen JS et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004 50 : 3432 43.
11. Johnsen AK, Schiff MH, Mease PJ et al. Comparison of 2 doses of etanercept (50 vs 100 mg) in active rheumatoid arthritis: a randomized double blind study. J Rheumatol 2006 33 : 659 64.
12. van de Putte LB, Atkins C, Malaise M et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004 63 : 508 16.
13. Weinblatt ME, Kremer JM, Bankhurst AD et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999 340 : 253 9.
14. Genovese M, Becker J-C, Schiff M et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005 353 : 1114 23.
15. Cohen SB, Emery P, Greenwald MW et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006 54 : 2793 806.
16. Hyrich KL, Lunt M, Watson KD et al. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 2007 56 : 13 20. (Pubitemid 46106174)
17. Karlsson J, Lars-erik K, Kapetanovic MC et al. Response to second or third Tnf-inhibitor in rheumatoid arthritis: results from an observational study. Arthritis Rheum 2007 56 : S310.